ヒト化マウス・ラットモデル市場 – 2030年までの世界予測

Humanized Mouse and Rat Models Market - Global Forecast to 2030

ヒト化マウス・ラットモデル市場 - タイプ(遺伝子モデル、細胞ベースモデル、ラットモデル)、用途(腫瘍学、免疫学、神経科学、毒性学、感染症)、エンドユーザー(製薬、バイオテクノロジー)、および地域別 - 2030年までの世界予測
Humanized Mouse and Rat Model Market by Type (Genetic Models, Cell-based Models, Rat Models), Application (Oncology, Immunology, Neuroscience, Toxicology, Infectious Diseases), End User (Pharma, Biotech), and Region - Global Forecast to 2030

商品番号 : SMB-33696

出版社MarketsandMarkets
出版年月2025年4月
ページ数255
図表数309
価格タイプシングルユーザライセンス
価格USD 4,950
種別英文調査報告書

Report Overview

The global humanized mouse and rat model market is anticipated to reach USD 409.8 million in 2030 from USD 276.2 million in 2025, with a significant CAGR of 8.2%.

世界のヒト化マウス・ラットモデル市場は、2025年の2億7,620万米ドルから2030年には4億980万米ドルに達し、8.2%という大幅なCAGRで成長すると予想されています。

The market is growing strongly at a high CAGR due to rising R&D investments of pharmaceutical and biopharmaceutical firms. As the pipeline of R&D expands, the requirement for outsourcing analytical testing is set to rise, in addition to the research initiatives on rare diseases and orphan drugs. Furthermore, the high costs of in-house drug development have also contributed to this trend. Industry players will likely witness healthy growth opportunities due to technological advancements, new drug discovery techniques, patent expirations, and rising demand for specialized testing services among end users.

製薬企業およびバイオ医薬品企業による研究開発投資の増加により、市場は高いCAGRで力強く成長しています。研究開発パイプラインの拡大に伴い、希少疾患やオーファンドラッグに関する研究活動に加え、分析試験のアウトソーシング需要も増加すると予想されます。さらに、自社開発における医薬品開発コストの高騰もこの傾向に拍車をかけています。業界関係者は、技術の進歩、新たな創薬技術、特許満了、そしてエンドユーザーによる専門的な試験サービスへの需要の高まりにより、健全な成長機会を享受できる可能性が高いでしょう。

ヒト化マウス・ラットモデル市場 - 2030年までの世界予測
humanized-mouse-model-market-Overview

“Humanized mouse model segment dominated the type segment in 2024”

Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. In 2024, humanized mouse models will have garnered the highest share in terms of revenue in the market. This segment is also expected to grow with the fastest CAGR through the forecast period. An increase in demand for cell-based humanized mouse models has contributed to the segment’s growth. These models are utilized in various applications, including the analysis of the safety and effectiveness of potential new drugs and in long-term studies in immuno-oncology, infectious diseases, and graft-versus-host disease.

“The immunology & infectious diseases segment accounted for the second largest share of the market in 2024”

The humanized mouse and rat model market is segmented based on application into oncology, immunology & infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. The immunology & infectious diseases segment is the second largest segment in the market in terms of revenue. Mouse models are used in immunology and inflammation studies as they help assess the physiological relevance of an experimental finding. Mouse models allow suitable alterations in the mouse genome at random or in specific regions, enabling a detailed study of immunological processes.

“Pharmaceutical & Biotechnology Companies will likely record the highest CAGR during the forecast period”

Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes. Pharmaceutical & biotechnology companies dominated the segment in 2024. The largest share of pharmaceutical and biotechnology companies in the humanized mouse and rat model market is due to the rising expenditure for innovative drug development and the growing preference for personalized medicine. However, the CROs & CDMOs segment is expected to register the highest growth during the forecast period due to the increasing number of pharmaceutical & biotechnology companies outsourcing preclinical studies and research activities for drug development to this end user segment.

“US to record the highest CAGR during the forecast period”

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the humanized mouse and rat model market in 2024 and is estimated to continue dominating during the forecast period. The US leads the North American market, driven by the presence of key players. The large share of the market is primarily driven by the rising funding for life sciences research and growing research on mAbs and biosimilars. The growing incidence of cancer is also expected to support market growth.

ヒト化マウス・ラットモデル市場 - 2030年までの世界予測 region
humanized-mouse-model-market-Region

In-depth interviews were conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the humanized mouse and rat model market.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 – 55%, Tier 2 – 25%, and Tier 3 – 20%
  • By Designation: C-level Executives – 45%, Directors – 30%, and Others – 25%
  • By Region: North America – 45%, Europe – 30%, Asia Pacific – 20%, Latin America – 3% and Middle East & Africa – 2%

Charles River Laboratories (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US), JSR Corporation (US) (Crown Biosciences), Champions Oncology, Inc. (US), CLEA Japan Inc. (Japan), genOway (France), Inotiv (US), Janvier Labs (France), Altogen Labs (US), Vitalstar Biotechnology (China), Ingenious Targeting Laboratory (US), Reaction Biology (US), Harbour BioMed (Netherlands), Oncodesign Services (France), Pharmatest Services (Finland), Ozgene Pty Ltd. (Australia), TransCure bioServices (France), Cyagen Biosciences (US), Aragen Life Sciences Ltd. (India), GemPharmatech (China), and Biocytogen (US) are some of the key players in the humanized mouse and rat model market.

ヒト化マウス・ラットモデル市場 - 2030年までの世界予測 ecosystem
humanized-mouse-model-market-Ecosystem

Research Coverage:

Humanized mouse and rat model market report is segmented based on type {[(humanized mouse models {genetic humanized mouse models and cell-based humanized mouse models (CD34 humanized mouse models, PBMC humanized mouse models, and BLT humanized mouse models)]} and humanized rat models), application (oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications, end user (pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East, Africa).

The report’s scope covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the humanized mouse and rat model market. A comprehensive analysis of the key players in the industry has been conducted to offer insights into their business overviews, products, key strategies, collaborations, partnerships, and agreements. This includes information about recent product launches, collaborations, acquisitions, and humanized mouse and rat model market developments.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the humanized mouse and rat model and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (rising use of humanized models in drug discovery research, emerging preclinical applications of humanized mouse models, government-funded initiatives for cancer research, and increasing R&D activities in the pharmaceutical & biotechnology industry), restraints (introduction of FDA Modernization Act 2.0/3.0, stringent regulatory compliance for ethical use of animal models), opportunities (growing preference for humanized PDX models, emergence of CRISPR in biomedical research), and challenges (alternatives for animal testing, limitations of humanized mouse models) influencing market growth.
  • Product Development/Innovation: Detailed insights on upcoming technologies in humanized mouse and rat models, research and development activities, and new product launches in the humanized mouse and rat model market.
  • Market Development: Comprehensive information about lucrative markets—the report analyses the market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the humanized mouse and rat model market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Charles River Laboratories (US), The Jackson Laboratory (JAX) (US), Inotiv (US), and genOway (France).

Table of Contents

1               INTRODUCTION              27

1.1           STUDY OBJECTIVES       27

1.2           MARKET DEFINITION   27

1.3           INCLUSIONS AND EXCLUSIONS 28

1.4           STUDY SCOPE   29

1.4.1        MARKET SEGMENTATION AND REGIONS COVERED                 29

1.4.2        YEARS CONSIDERED      30

1.4.3        CURRENCY CONSIDERED            30

1.5           STAKEHOLDERS               30

1.6           SUMMARY OF CHANGES               31

2               RESEARCH METHODOLOGY       32

2.1           RESEARCH DATA              32

2.1.1        SECONDARY DATA          33

2.1.1.1    Objectives of secondary research       33

2.1.2        PRIMARY DATA 34

2.1.2.1    Objectives of primary research           34

2.2           MARKET SIZE ESTIMATION         35

2.2.1        GLOBAL MARKET ESTIMATION 35

2.2.2        SEGMENTAL MARKET ESTIMATION        38

2.3           GROWTH RATE PROJECTIONS  39

2.4           DATA TRIANGULATION                41

2.5           RESEARCH ASSUMPTIONS           42

2.6           RESEARCH LIMITATIONS             43

2.7           RISK ANALYSIS  43

3               EXECUTIVE SUMMARY  44

4               PREMIUM INSIGHTS       47

4.1           HUMANIZED MOUSE AND RAT MODEL MARKET OVERVIEW          47

4.2           NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY END USER AND COUNTRY, 2024          48

4.3           HUMANIZED MOUSE AND RAT MODEL MARKET, BY KEY COUNTRY            49

4.4           HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER            49

5               MARKET OVERVIEW       50

5.1           INTRODUCTION              50

5.2           MARKET DYNAMICS       50

5.2.1        DRIVERS               51

5.2.1.1    Rising use of humanized models in drug discovery research                 51

5.2.1.2    Emerging preclinical applications of humanized mouse models                 53

5.2.1.3    Government-funded initiatives for cancer research        53

5.2.1.4    Increasing R&D activities in pharmaceutical & biotechnology industry  54

5.2.2        RESTRAINTS      55

5.2.2.1    Introduction of FDA Modernization Act 2.0/3.0             55

5.2.2.2    Stringent regulatory compliance for ethical use of animal models                 55

5.2.3        OPPORTUNITIES              56

5.2.3.1    Growing preference for humanized PDX models            56

5.2.3.2    Emergence of CRISPR in biomedical research                56

5.2.4        CHALLENGES    57

5.2.4.1    Alternative methods for animal testing             57

5.2.4.2    Limitations of humanized mouse models         57

5.3           TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS            58

5.4           PRICING ANALYSIS          59

5.4.1        AVERAGE SELLING PRICE TREND OF PRODUCTS,

BY KEY PLAYER, 2022–2024            59

5.4.2        AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION         60

5.5           SUPPLY CHAIN ANALYSIS             62

5.6           VALUE CHAIN ANALYSIS               63

5.7           ECOSYSTEM ANALYSIS  65

5.8           INVESTMENT AND FUNDING SCENARIO               67

5.9           TECHNOLOGY ANALYSIS             68

5.9.1        KEY TECHNOLOGIES     68

5.9.1.1    CRISPR-Cas9        68

5.9.1.2    Tissue engineering                68

5.9.1.3    In vivo imaging     69

5.9.2        COMPLEMENTARY TECHNOLOGIES       69

5.9.2.1    3D cell culture      69

5.9.2.2    Organs-on-Chips 69

5.9.2.3    Biomarker discovery             69

5.9.3        ADJACENT TECHNOLOGIES       70

5.9.3.1    Proteomics             70

5.9.3.2    Microfluidics         70

5.9.3.3    Regenerative medicine        70

5.10         PATENT ANALYSIS          70

5.11         TRADE ANALYSIS             74

5.12         KEY CONFERENCES AND EVENTS, 2025–2026        76

5.13         REGULATORY LANDSCAPE         76

5.13.1      REGULATORY FRAMEWORK       76

5.13.2      NORTH AMERICA             76

5.13.3      EUROPE               77

5.13.4      ASIA PACIFIC     79

5.13.4.1  China      79

5.13.4.2  Japan      79

5.13.4.3  India       80

5.13.4.4  Australia 80

5.13.5      LATIN AMERICA                81

5.13.6      MIDDLE EAST & AFRICA                81

5.13.7      REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  81

5.14         PORTER’S FIVE FORCES ANALYSIS           83

5.14.1      THREAT OF NEW ENTRANTS      84

5.14.2      THREAT OF SUBSTITUTES          84

5.14.3      BARGAINING POWER OF SUPPLIERS       85

5.14.4      BARGAINING POWER OF BUYERS             85

5.14.5      INTENSITY OF COMPETITIVE RIVALRY 85

5.15         KEY STAKEHOLDERS AND BUYING CRITERIA     85

5.15.1      KEY STAKEHOLDERS IN BUYING PROCESS           85

5.15.2      KEY BUYING CRITERIA, BY END USER    86

5.16         IMPACT OF AI ON HUMANIZED MOUSE AND RAT MODEL MARKET              87

5.16.1      INTRODUCTION              87

5.16.2      MARKET POTENTIAL OF AI IN HUMANIZED MOUSE AND RAT MODELS          87

5.16.3      AI USE CASES     88

5.16.4      KEY COMPANIES IMPLEMENTING AI      88

5.16.5      FUTURE OF GENERATIVE AI IN HUMANIZED MOUSE AND RAT MODEL MARKET          88

6               HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE     89

6.1           INTRODUCTION              90

6.2           HUMANIZED MOUSE MODELS  91

6.2.1        GENETIC HUMANIZED MOUSE MODELS               94

6.2.1.1    Advancements in genetical engineering technologies to drive market    94

6.2.2        CELL-BASED HUMANIZED MOUSE MODELS        96

6.2.2.1    CD34 humanized mouse models       98

6.2.2.1.1 Rising demand for stem cell therapy to propel market   98

6.2.2.2    PBMC humanized mouse models      100

6.2.2.2.1 Growing prevalence of infectious diseases to boost demand                 100

6.2.2.3    BLT humanized mouse models          103

6.2.2.3.1 Surge in HIV cases to drive market   103

6.3           HUMANIZED RAT MODELS         105

6.3.1        PREFERENCE FOR SRG RAT MODELS FOR RESEARCH STUDIES WITH LARGE SAMPLE SIZE SUPPORTS THE SEGMENT GROWTH             105

7               HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER            107

7.1           INTRODUCTION              108

7.2           PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES                 108

7.2.1        GROWING ADOPTION OF HU-MICE MODELS IN VACCINE DEVELOPMENT TO BOOST SEGMENT GROWTH                 108

7.3           CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS             111

7.3.1        OUTSOURCING OF DRUG DISCOVERY SERVICES BY PHARMA & BIOTECH COMPANIES TO PROPEL MARKET                 111

7.4           ACADEMIC & RESEARCH INSTITUTES    113

7.4.1        SUPPORTIVE FUNDING INVESTMENTS FOR LIFE SCIENCE RESEARCH TO DRIVE MARKET                113

8               HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION   116

8.1           INTRODUCTION              117

8.2           ONCOLOGY        117

8.2.1        UTILIZATION OF MOUSE MODELS IN CANCER RESEARCH TO DRIVE MARKET  117

8.3           IMMUNOLOGY AND INFECTIOUS DISEASES       120

8.3.1        DEVELOPMENT OF ADVANCED MODELS FOR TREATMENT OF RARE DISEASES TO DRIVE MARKET      120

8.4           NEUROSCIENCE               122

8.4.1        RISING INCIDENCE OF CNS DISORDERS TO DRIVE MARKET               122

8.5           TOXICOLOGY    124

8.5.1        INCREASING CLINICAL TRIALS FOR TOXICOLOGY STUDIES TO SUPPORT MARKET GROWTH           124

8.6           HEMATOPOIESIS             126

8.6.1        RISING DEMAND FOR STEM CELL THERAPY TO DRIVE MARKET               126

8.7           OTHER APPLICATIONS 128

9               HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION                131

9.1           INTRODUCTION              132

9.2           NORTH AMERICA             133

9.2.1        MACROECONOMIC OUTLOOK OF NORTH AMERICA                 136

9.2.2        US           136

9.2.2.1    Growing research initiatives on mAbs and biosimilars to drive market    136

9.2.3        CANADA               139

9.2.3.1    Government initiatives on stem cell research to drive market                 139

9.3           EUROPE               141

9.3.1        MACROECONOMIC OUTLOOK OF EUROPE         143

9.3.2        GERMANY           145

9.3.2.1    Rising pharmaceutical R&D expenditure to drive market                 145

9.3.3        UK          147

9.3.3.1    Growing investments in cancer research to drive market                 147

9.3.4        FRANCE                149

9.3.4.1    Rising initiatives for genomics research to support market growth                 149

9.3.5        ITALY    151

9.3.5.1    Robust pharmaceutical production to fuel market          151

9.3.6        SPAIN    153

9.3.6.1    Rising growth in biotech industry to drive market          153

9.3.7        REST OF EUROPE             155

9.4           ASIA PACIFIC     157

9.4.1        MACROECONOMIC OUTLOOK OF ASIA PACIFIC                 161

9.4.2        CHINA  161

9.4.2.1    High growth in pharmaceutical industry to drive market                 161

9.4.3        JAPAN   164

9.4.3.1    Growing research collaborations among pharmaceutical companies to drive market  164

9.4.4        INDIA    166

9.4.4.1    Growth in biotech industry to drive market     166

9.4.5        SOUTH KOREA  169

9.4.5.1    Rising government-funded investments for pharmaceutical R&D to drive market      169

9.4.6        AUSTRALIA         171

9.4.6.1    Rising biomedical research projects to drive market       171

9.4.7        REST OF ASIA PACIFIC   173

9.5           LATIN AMERICA                175

9.5.1        GROWING PRESENCE OF PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO PROPEL MARKET     175

9.5.2        MACROECONOMIC OUTLOOK OF LATIN AMERICA                 177

9.6           MIDDLE EAST   178

9.6.1        GROWING PHARMACEUTICAL MARKET IN COUNTRIES TO SUPPORT MARKET GROWTH              178

9.6.2        MACROECONOMIC OUTLOOK FOR MIDDLE EAST                 180

9.7           AFRICA 181

9.7.1        GROWING PHARMACEUTICAL INDUSTRY TO SUPPORT MARKET GROWTH          181

9.7.2        MACROECONOMIC OUTLOOK FOR AFRICA        183

10            COMPETITIVE LANDSCAPE         184

10.1         INTRODUCTION              184

10.2         KEY PLAYER STRATEGY/RIGHT TO WIN                184

10.2.1      OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMANIZED MOUSE AND RAT MODEL MARKET         185

10.3         REVENUE ANALYSIS, 2020−2024                 187

10.4         MARKET SHARE ANALYSIS, 2024                 187

10.4.1      HUMANIZED MOUSE AND RAT MODEL MARKET                 188

10.5         COMPANY VALUATION AND FINANCIAL METRICS                 190

10.5.1      FINANCIAL METRICS      190

10.6         BRAND/PRODUCT COMPARISON             191

10.7         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 192

10.7.1      STARS   192

10.7.2      EMERGING LEADERS     192

10.7.3      PERVASIVE PLAYERS      192

10.7.4      PARTICIPANTS 192

10.7.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         194

10.7.5.1  Company footprint               194

10.7.5.2  Region footprint   195

10.7.5.3  Type footprint       196

10.7.5.4  Application footprint            197

10.8         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        198

10.8.1      PROGRESSIVE COMPANIES         198

10.8.2      RESPONSIVE COMPANIES            198

10.8.3      DYNAMIC COMPANIES  198

10.8.4      STARTING BLOCKS         198

10.8.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES                 200

10.8.5.1  Detailed list of key startups/SMEs    200

10.8.5.2  Competitive benchmarking of key startups/SMEs          201

10.9         COMPETITIVE SCENARIO             202

10.9.1      PRODUCT LAUNCHES & APPROVALS     202

10.9.2      DEALS  202

10.9.3      EXPANSIONS     204

11            COMPANY PROFILES      205

11.1         KEY PLAYERS     205

11.1.1      CHARLES RIVER LABORATORIES               205

11.1.1.1  Business overview 205

11.1.1.2  Products offered   206

11.1.1.3  Recent developments           207

11.1.1.3.1                Deals      207

11.1.1.3.2                Other developments             207

11.1.1.4  MnM view              208

11.1.1.4.1                Key strengths        208

11.1.1.4.2                Strategic choices   208

11.1.1.4.3                Weaknesses and competitive threats 208

11.1.2      THE JACKSON LABORATORY      209

11.1.2.1  Business overview 209

11.1.2.2  Products offered   211

11.1.2.3  Recent developments           212

11.1.2.3.1                Deals      212

11.1.2.4  MnM view              212

11.1.2.4.1                Key strengths        212

11.1.2.4.2                Strategic choices   212

11.1.2.4.3                Weaknesses and competitive threats 212

11.1.3      INOTIV 213

11.1.3.1  Business overview 213

11.1.3.2  Products offered   215

11.1.3.3  Recent developments           216

11.1.3.3.1                Deals      216

11.1.3.4  MnM view              217

11.1.3.4.1                Key strengths        217

11.1.3.4.2                Strategic choices   217

11.1.3.4.3                Weaknesses and competitive threats 217

11.1.4      GENOWAY          218

11.1.4.1  Business overview 218

11.1.4.2  Products offered   218

11.1.4.3  Recent developments           220

11.1.4.3.1                Other developments             220

11.1.4.4  MnM view              220

11.1.4.4.1                Key strengths        220

11.1.4.4.2                Strategic choices   220

11.1.4.4.3                Weaknesses and competitive threats 220

11.1.5      TACONIC BIOSCIENCES, INC.     221

11.1.5.1  Business overview 221

11.1.5.2  Products offered   222

11.1.5.3  Recent developments           223

11.1.5.3.1                Product launches  223

11.1.5.3.2                Expansions             223

11.1.6      JSR CORPORATION         224

11.1.6.1  Business overview 224

11.1.6.2  Products offered   225

11.1.6.3  Recent developments           226

11.1.6.3.1                Deals      226

11.1.6.3.2                Expansions             227

11.1.7      CHAMPIONS ONCOLOGY, INC.  228

11.1.7.1  Business overview 228

11.1.7.2  Products offered   229

11.1.8      JANVIER LABS    230

11.1.8.1  Business overview 230

11.1.8.2  Products offered   230

11.1.8.3  Recent developments           231

11.1.8.3.1                Deals      231

11.1.9      VITALSTAR BIOTECHNOLOGY  232

11.1.9.1  Business overview 232

11.1.9.2  Products offered   232

11.1.10   INGENIOUS TARGETING LABORATORY 233

11.1.10.1                 Business overview 233

11.1.10.2                 Products offered   234

11.1.11   HARBOUR BIOMED         235

11.1.11.1                 Business overview 235

11.1.11.2                 Products offered   236

11.1.11.3                 Recent developments           236

11.1.11.3.1             Deals      236

11.1.12   ONCODESIGN SERVICES               237

11.1.12.1                 Business overview 237

11.1.12.2                 Products offered   237

11.1.13   PHARMATEST SERVICES               238

11.1.13.1                 Business overview 238

11.1.13.2                 Products offered   238

11.2         OTHER PLAYERS              239

11.2.1      OZGENE PTY LTD.           239

11.2.2      CLEA JAPAN, INC.             240

11.2.3      ALTOGEN LABS                 241

11.2.4      REACTION BIOLOGY      242

11.2.5      TRANSCURE BIOSERVICES          243

11.2.6      CYAGEN               244

11.2.7      ARAGEN LIFE SCIENCES LTD.     245

11.2.8      BIOCYTOGEN   246

11.2.9      GEMPHARMATECH         247

12            APPENDIX           248

12.1         DISCUSSION GUIDE        248

12.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                251

12.3         CUSTOMIZATION OPTIONS        253

12.4         RELATED REPORTS         253

12.5         AUTHOR DETAILS           254

LIST OF TABLES

TABLE 1                HUMANIZED MOUSE AND RAT MODEL MARKET: INCLUSIONS AND EXCLUSIONS             28

TABLE 2                IMPACT ANALYSIS OF SUPPLY AND DEMAND-SIDE FACTORS  40

TABLE 3                HUMANIZED MOUSE AND RAT MODEL MARKET: RISK ANALYSIS              43

TABLE 4                HUMANIZED MOUSE AND RAT MODEL MARKET: IMPACT ANALYSIS OF

MARKET DYNAMICS       51

TABLE 5                NUMBER OF R&D PRODUCTS, BY INDICATION (2024)    54

TABLE 6                AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER,

2022–2024 (USD MILLION)            59

TABLE 7                AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION,

2022–2024 (USD)                60

TABLE 8                AVERAGE SELLING PRICE TREND OF KEY PRODUCTS (HUMANIZED MOUSE MODELS), BY REGION, 2022–2024 (USD)          61

TABLE 9                HUMANIZED MOUSE AND RAT MODEL MARKET: ROLE OF COMPANIES IN ECOSYSTEM                66

TABLE 10              INVESTMENT AND FUNDING ACTIVITY, BY KEY PLAYER, 2021−2025          67

TABLE 11              HUMANIZED MOUSE AND RAT MODEL MARKET: INNOVATIONS AND

PATENT REGISTRATIONS, 2021–2024       72

TABLE 12              IMPORT DATA FOR LABORATORY MOUSE                 74

TABLE 13              EXPORT DATA FOR LABORATORY MOUSE                 75

TABLE 14              HUMANIZED MOUSE AND RAT MODEL MARKET: KEY CONFERENCES

AND EVENTS, 2025–2026                 76

TABLE 15              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  81

TABLE 16              EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  82

TABLE 17              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  82

TABLE 18              REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  83

TABLE 19              HUMANIZED MOUSE AND RAT MODEL MARKET: PORTER’S FIVE FORCES ANALYSIS       83

TABLE 20              INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)    86

TABLE 21              KEY BUYING CRITERIA, BY END USER    86

TABLE 22             HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE,

2023–2030 (USD MILLION)            90

TABLE 23             HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE,

2023–2030 (THOUSAND UNITS)  90

TABLE 24              HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)                92

TABLE 25              HUMANIZED MOUSE MODELS MARKET, BY REGION, 2023–2030 (USD MILLION)          93

TABLE 26              NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               93

TABLE 27              EUROPE: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            93

TABLE 28              ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            94

TABLE 29              GENETIC HUMANIZED MOUSE MODELS MARKET, BY REGION,

2023–2030 (USD MILLION)            95

TABLE 30              NORTH AMERICA: GENETIC HUMANIZED MOUSE MODELS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               95

TABLE 31              EUROPE: GENETIC HUMANIZED MOUSE MODELS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               95

TABLE 32              ASIA PACIFIC: GENETIC HUMANIZED MOUSE MODELS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               96

TABLE 33              CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         96

TABLE 34              CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY REGION, 2023–2030 (USD MILLION)   97

TABLE 35              NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               97

TABLE 36              EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               97

TABLE 37              ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               98

TABLE 38              CD34 HUMANIZED MODELS MARKET, BY REGION, 2023–2030 (USD MILLION)          99

TABLE 39              NORTH AMERICA: CD34 HUMANIZED MODELS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               99

TABLE 40              EUROPE: CD34 HUMANIZED MODELS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            100

TABLE 41              ASIA PACIFIC: CD34 HUMANIZED MODELS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            100

TABLE 42              PBMC HUMANIZED MICE MODELS MARKET, BY REGION,

2023–2030 (USD MILLION)            101

TABLE 43              NORTH AMERICA: PBMC HUMANIZED MICE MODELS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               102

TABLE 44              EUROPE: PBMC HUMANIZED MICE MODELS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               102

TABLE 45              ASIA PACIFIC: PBMC HUMANIZED MICE MODELS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               102

TABLE 46              BLT HUMANIZED MOUSE MODELS MARKET, BY REGION,

2023–2030 (USD MILLION)            103

TABLE 47              NORTH AMERICA: BLT HUMANIZED MOUSE MODELS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               104

TABLE 48              EUROPE: BLT HUMANIZED MOUSE MODELS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               104

TABLE 49              ASIA PACIFIC: BLT HUMANIZED MOUSE MODELS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               104

TABLE 50              HUMANIZED RAT MODELS MARKET, BY REGION, 2023–2030 (USD MILLION)          105

TABLE 51              NORTH AMERICA: HUMANIZED RAT MODELS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               106

TABLE 52              EUROPE: HUMANIZED RAT MODELS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            106

TABLE 53              ASIA PACIFIC: HUMANIZED RAT MODELS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            106

TABLE 54             HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER,

2023–2030 (USD MILLION)            108

TABLE 55              USE OF HUMANIZED MICE MODELS IN DEVELOPED AND TESTED VACCINES    109

TABLE 56              HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)          110

TABLE 57              NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,

2023–2030 (USD MILLION)            110

TABLE 58              EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   110

TABLE 59              ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,

2023–2030 (USD MILLION)            111

TABLE 60              HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS,

BY REGION, 2023–2030 (USD MILLION)   112

TABLE 61              NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS

AND CDMOS, BY COUNTRY, 2023–2030 (USD MILLION)  112

TABLE 62              EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2023–2030 (USD MILLION)       112

TABLE 63              ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS

AND CDMOS, BY COUNTRY, 2023–2030 (USD MILLION)  113

TABLE 64              HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)       114

TABLE 65              NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)               114

TABLE 66              EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)     115

TABLE 67              ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)     115

TABLE 68             HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            117

TABLE 69              HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY,

BY REGION, 2023–2030 (USD MILLION)   119

TABLE 70              NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 119

TABLE 71              EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               119

TABLE 72              ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               120

TABLE 73              HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY

AND INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)            121

TABLE 74              NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY,

2023–2030 (USD MILLION)            121

TABLE 75              EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY

AND INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)            121

TABLE 76              ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)         122

TABLE 77              HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE,

BY REGION, 2023–2030 (USD MILLION)   123

TABLE 78              NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2023–2030 (USD MILLION)       123

TABLE 79              EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE,

BY COUNTRY, 2023–2030 (USD MILLION)               123

TABLE 80              ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2023–2030 (USD MILLION) 124

TABLE 81              HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY,

BY REGION, 2023–2030 (USD MILLION)   125

TABLE 82              NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)       125

TABLE 83              EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               125

TABLE 84              ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               126

TABLE 85              HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS,

BY REGION, 2023–2030 (USD MILLION)   127

TABLE 86              NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET

FOR HEMATOPOIESIS, BY COUNTRY, 2023–2030 (USD MILLION)                 127

TABLE 87              EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS,

BY COUNTRY, 2023–2030 (USD MILLION)               127

TABLE 88              ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2023–2030 (USD MILLION)       128

TABLE 89              HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS,

BY REGION, 2023–2030 (USD MILLION)   129

TABLE 90              NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET

FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)            129

TABLE 91              EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)            129

TABLE 92              ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)            130

TABLE 93             HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION,

2023–2030 (USD MILLION)            132

TABLE 94              NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               134

TABLE 95              NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY TYPE, 2023–2030 (USD MILLION)         134

TABLE 96              NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         134

TABLE 97              NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         135

TABLE 98              NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       135

TABLE 99              NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY END USER, 2023–2030 (USD MILLION)               135

TABLE 100            KEY MACROECONOMIC INDICATORS OF NORTH AMERICA             136

TABLE 101            US: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY TYPE, 2023–2030 (USD MILLION)         137

TABLE 102            US: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)                137

TABLE 103            US: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         138

TABLE 104            US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            138

TABLE 105            US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER,

2023–2030 (USD MILLION)            138

TABLE 106            CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE,

2023–2030 (USD MILLION)            139

TABLE 107            CANADA: HUMANIZED MOUSE MODELS MARKET, BY TYPE,

2023–2030 (USD MILLION)            140

TABLE 108            CANADA: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         140

TABLE 109            CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       140

TABLE 110            CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY END USER, 2023–2030 (USD MILLION)               141

TABLE 111            EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               141

TABLE 112            EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY TYPE, 2023–2030 (USD MILLION)         142

TABLE 113            EUROPE: HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         142

TABLE 114            EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         142

TABLE 115            EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       143

TABLE 116            EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY END USER, 2023–2030 (USD MILLION)               143

TABLE 117            KEY MACROECONOMIC INDICATORS OF EUROPE               144

TABLE 118            GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY TYPE, 2023–2030 (USD MILLION)         145

TABLE 119            GERMANY: HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         145

TABLE 120            GERMANY: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         146

TABLE 121            GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       146

TABLE 122            GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY END USER, 2023–2030 (USD MILLION)               146

TABLE 123            UK: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY TYPE, 2023–2030 (USD MILLION)         147

TABLE 124            UK: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)                147

TABLE 125            UK: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         148

TABLE 126            UK: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       148

TABLE 127            UK: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY END USER, 2023–2030 (USD MILLION)               148

TABLE 128            FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY TYPE, 2023–2030 (USD MILLION)         149

TABLE 129            FRANCE: HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         150

TABLE 130            FRANCE: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         150

TABLE 131            FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       150

TABLE 132            FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY END USER, 2023–2030 (USD MILLION)               151

TABLE 133            ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY TYPE, 2023–2030 (USD MILLION)         152

TABLE 134            ITALY: HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         152

TABLE 135            ITALY: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         152

TABLE 136            ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       153

TABLE 137            ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY END USER, 2023–2030 (USD MILLION)               153

TABLE 138            SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY TYPE, 2023–2030 (USD MILLION)         154

TABLE 139            SPAIN: HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         154

TABLE 140            SPAIN: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         154

TABLE 141            SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       155

TABLE 142            SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY END USER, 2023–2030 (USD MILLION)               155

TABLE 143            REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY TYPE, 2023–2030 (USD MILLION)         156

TABLE 144            REST OF EUROPE: HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         156

TABLE 145            REST OF EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         156

TABLE 146            REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       157

TABLE 147            REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY END USER, 2023–2030 (USD MILLION)               157

TABLE 148            ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               159

TABLE 149            ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY TYPE, 2023–2030 (USD MILLION)         159

TABLE 150            ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         159

TABLE 151            ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         160

TABLE 152            ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       160

TABLE 153            ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY END USER, 2023–2030 (USD MILLION)               160

TABLE 154            KEY MACROECONOMIC INDICATORS OF ASIA PACIFIC                161

TABLE 155            CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY TYPE, 2023–2030 (USD MILLION)         162

TABLE 156            CHINA: HUMANIZED MOUSE MODELS MARKET, BY TYPE,

2023–2030 (USD MILLION)            163

TABLE 157            CHINA: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         163

TABLE 158            CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       163

TABLE 159            CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY END USER, 2023–2030 (USD MILLION)               164

TABLE 160            JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY TYPE, 2023–2030 (USD MILLION)         165

TABLE 161            JAPAN: HUMANIZED MOUSE MODELS MARKET, BY TYPE,

2023–2030 (USD MILLION)            165

TABLE 162            JAPAN: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         165

TABLE 163            JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       166

TABLE 164            JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY END USER, 2023–2030 (USD MILLION)               166

TABLE 165            INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY TYPE, 2023–2030 (USD MILLION)         167

TABLE 166            INDIA: HUMANIZED MOUSE MODELS MARKET, BY TYPE,

2023–2030 (USD MILLION)            167

TABLE 167            INDIA: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         168

TABLE 168            INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       168

TABLE 169            INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY END USER, 2023–2030 (USD MILLION)               168

TABLE 170            SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY TYPE, 2023–2030 (USD MILLION)         169

TABLE 171            SOUTH KOREA: HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         170

TABLE 172            SOUTH KOREA: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         170

TABLE 173            SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       170

TABLE 174            SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY END USER, 2023–2030 (USD MILLION)               171

TABLE 175            AUSTRALIA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY TYPE, 2023–2030 (USD MILLION)         171

TABLE 176            AUSTRALIA: HUMANIZED MOUSE MODELS MARKET, BY TYPE,

2023–2030 (USD MILLION)            172

TABLE 177            AUSTRALIA: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         172

TABLE 178            AUSTRALIA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       172

TABLE 179            AUSTRALIA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY END USER, 2023–2030 (USD MILLION)               173

TABLE 180            REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY TYPE, 2023–2030 (USD MILLION)         173

TABLE 181            REST OF ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         173

TABLE 182            REST OF ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         174

TABLE 183            REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       174

TABLE 184            REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY END USER, 2023–2030 (USD MILLION)               174

TABLE 185            LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY TYPE, 2023–2030 (USD MILLION)         175

TABLE 186            LATIN AMERICA: HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         175

TABLE 187            LATIN AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         176

TABLE 188            LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       176

TABLE 189            LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY END USER, 2023–2030 (USD MILLION)               176

TABLE 190            KEY MACROECONOMIC INDICATORS OF LATIN AMERICA             177

TABLE 191            MIDDLE EAST: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY TYPE, 2023–2030 (USD MILLION)         178

TABLE 192            MIDDLE EAST: HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         178

TABLE 193            MIDDLE EAST: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         179

TABLE 194            MIDDLE EAST: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       179

TABLE 195            MIDDLE EAST: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY END USER, 2023–2030 (USD MILLION)               179

TABLE 196            KEY MACROECONOMIC INDICATORS OF MIDDLE EAST   180

TABLE 197            AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY TYPE, 2023–2030 (USD MILLION)         181

TABLE 198          AFRICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE,

2023–2030 (USD MILLION)            181

TABLE 199            AFRICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         182

TABLE 200            AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       182

TABLE 201            AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET,

BY END USER, 2023–2030 (USD MILLION)               182

TABLE 202            KEY MACROECONOMIC INDICATORS OF AFRICA 183

TABLE 203            STRATEGIES ADOPTED BY KEY PLAYERS IN HUMANIZED MOUSE

AND RAT MODEL MARKET, 2021−2024   185

TABLE 204            HUMANIZED MOUSE AND RAT MODEL MARKET: DEGREE OF COMPETITION    188

TABLE 205            HUMANIZED MOUSE AND RAT MODEL MARKET: REGION FOOTPRINT 195

TABLE 206            HUMANIZED MOUSE AND RAT MODEL MARKET: TYPE FOOTPRINT       196

TABLE 207            HUMANIZED MOUSE AND RAT MODEL MARKET: APPLICATION FOOTPRINT     197

TABLE 208            HUMANIZED MOUSE AND RAT MODEL MARKET: KEY STARTUPS/SMES 200

TABLE 209            HUMANIZED MOUSE AND RAT MODEL MARKET: COMPETITIVE BENCHMARKING

OF KEY START UPS/SMES             201

TABLE 210            HUMANIZED MOUSE AND RAT MODEL MARKET: PRODUCT LAUNCHES,

JANUARY 2021–MARCH 2025         202

TABLE 211            HUMANIZED MOUSE AND RAT MODEL MARKET: DEALS, JANUARY

2021–MARCH 2025             203

TABLE 212            HUMANIZED MOUSE AND RAT MODEL MARKET: EXPANSIONS,

JANUARY 2021–MARCH 2025         204

TABLE 213            CHARLES RIVER LABORATORIES: COMPANY OVERVIEW          205

TABLE 214            CHARLES RIVER LABORATORIES: PRODUCTS OFFERED             206

TABLE 215            CHARLES RIVER LABORATORIES: DEALS, JANUARY 2021–JANUARY 2025     207

TABLE 216            CHARLES RIVER LABORATORIES: OTHER DEVELOPMENTS,

JANUARY 2021–JANUARY 2025     207

TABLE 217            THE JACKSON LABORATORY: COMPANY OVERVIEW          209

TABLE 218            THE JACKSON LABORATORY: PRODUCTS OFFERED             211

TABLE 219            THE JACKSON LABORATORY: DEALS, JANUARY 2021–JANUARY 2025         212

TABLE 220            INOTIV: COMPANY OVERVIEW 213

TABLE 221            INOTIV: PRODUCTS OFFERED  215

TABLE 222            INOTIV: DEALS, JANUARY 2021–JANUARY 2025                 216

TABLE 223            GENOWAY: COMPANY OVERVIEW           218

TABLE 224            GENOWAY: PRODUCTS OFFERED            218

TABLE 225            GENOWAY: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025         220

TABLE 226            TACONIC BIOSCIENCES, INC.: COMPANY OVERVIEW          221

TABLE 227            TACONIC BIOSCIENCES, INC.: PRODUCTS OFFERED             222

TABLE 228            TACONIC BIOSCIENCES, INC.: PRODUCT LAUNCHES,

JANUARY 2021–JANUARY 2025     223

TABLE 229            TACONIC BIOSCIENCES, INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025     223

TABLE 230            JSR CORPORATION: COMPANY OVERVIEW                 224

TABLE 231            JSR CORPORATION: PRODUCTS OFFERED                 225

TABLE 232            JSR CORPORATION: DEALS, JANUARY 2021–JANUARY 2025    226

TABLE 233            JSR CORPORATION: EXPANSIONS, JANUARY 2021–JANUARY 2025         227

TABLE 234            CHAMPIONS ONCOLOGY, INC.: COMPANY OVERVIEW          228

TABLE 235            CHAMPIONS ONCOLOGY, INC.: PRODUCTS OFFERED             229

TABLE 236            JANVIER LABS: COMPANY OVERVIEW    230

TABLE 237            JANVIER LABS: PRODUCTS OFFERED     230

TABLE 238            JANVIER LABS: DEALS, JANUARY 2021–JANUARY 2025        231

TABLE 239            VITALSTAR BIOTECHNOLOGY: COMPANY OVERVIEW          232

TABLE 240            VITALSTAR BIOTECHNOLOGY: PRODUCTS OFFERED             232

TABLE 241            INGENIOUS TARGETING LABORATORY: COMPANY OVERVIEW   233

TABLE 242            INGENIOUS TARGETING LABORATORY: PRODUCTS OFFERED    234

TABLE 243            HARBOUR BIOMED: COMPANY OVERVIEW                 235

TABLE 244            HARBOUR BIOMED: PRODUCTS OFFERED                 236

TABLE 245            HARBOUR BIOMED: DEALS, JANUARY 2021–JANUARY 2025    236

TABLE 246            ONCODESIGN SERVICES: COMPANY OVERVIEW                 237

TABLE 247            ONCODESIGN SERVICES: PRODUCTS OFFERED                 237

TABLE 248            PHARMATEST SERVICES: COMPANY OVERVIEW                 238

TABLE 249            PHARMATEST SERVICES: PRODUCTS OFFERED                 238

TABLE 250            OZGENE PTY LTD.: COMPANY OVERVIEW                 239

TABLE 251            CLEA JAPAN, INC.: COMPANY OVERVIEW                 240

TABLE 252            ALTOGEN LABS: COMPANY OVERVIEW 241

TABLE 253            REACTION BIOLOGY: COMPANY OVERVIEW                 242

TABLE 254            TRANSCURE BIOSERVICES: COMPANY OVERVIEW          243

TABLE 255            CYAGEN: COMPANY OVERVIEW                244

TABLE 256            ARAGEN LIFE SCIENCES LTD.: COMPANY OVERVIEW          245

TABLE 257            BIOCYTOGEN: COMPANY OVERVIEW    246

TABLE 258            GEMPHARMATECH: COMPANY OVERVIEW                 247

LIST OF FIGURES

FIGURE 1              HUMANIZED MOUSE AND RAT MODEL MARKET SEGMENTATION AND

REGIONS CONSIDERED 29

FIGURE 2              HUMANIZED MOUSE AND RAT MODEL MARKET: YEARS CONSIDERED  30

FIGURE 3              HUMANIZED MOUSE AND RAT MODEL MARKET: RESEARCH DESIGN     32

FIGURE 4              BREAKDOWN OF PRIMARY INTERVIEWS: BY RESPONDENT,

DESIGNATION, AND REGION     34

FIGURE 5              GLOBAL HUMANIZED MOUSE AND RAT MODEL MARKET SIZE ESTIMATION, 2024               35

FIGURE 6              COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2024           36

FIGURE 7              REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF CHARLES RIVER LABORATORIES, 2024        36

FIGURE 8              MARKET SIZE VALIDATION FROM PRIMARIES                 38

FIGURE 9              MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH                38

FIGURE 10            HUMANIZED MOUSE AND RAT MODEL MARKET: CAGR PROJECTIONS, 2025–2030              40

FIGURE 11            HUMANIZED MOUSE AND RAT MODEL MARKET: DATA TRIANGULATION            41

FIGURE 12           HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE,

2025 VS. 2030 (USD MILLION)      44

FIGURE 13           HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION,

2025 VS. 2030 (USD MILLION)      45

FIGURE 14           HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER,

2025 VS. 2030 (USD MILLION)      45

FIGURE 15            REGIONAL SNAPSHOT OF HUMANIZED MOUSE AND RAT MODEL

MARKET, 2025–2030          46

FIGURE 16            RISING USE OF HUMANIZED MODELS IN DRUG DISCOVERY RESEARCH

TO DRIVE MARKET         47

FIGURE 17            PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT ACCOUNTED

FOR LARGEST MARKET SHARE IN US IN 2024       48

FIGURE 18            CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD         49

FIGURE 19            PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT DOMINATED MARKET IN 2024    49

FIGURE 20            HUMANIZED MOUSE AND RAT MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    50

FIGURE 21            NUMBER OF CLINICAL TRIALS REGISTERED FOR CANCER IMMUNOTHERAPIES, 2020–2024     52

FIGURE 22            TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS   58

FIGURE 23            AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER,

2022–2024 (USD)                59

FIGURE 24            AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION,

2022–2024 (USD)                60

FIGURE 25            AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION,

2022–2024 (USD)                61

FIGURE 26            HUMANIZED MOUSE AND RAT MODEL MARKET: SUPPLY CHAIN ANALYSIS         63

FIGURE 27            HUMANIZED MOUSE AND RAT MODEL MARKET: VALUE CHAIN ANALYSIS           63

FIGURE 28            HUMANIZED MOUSE AND RAT MODEL MARKET ECOSYSTEM       66

FIGURE 29            INVESTMENT AND FUNDING SCENARIO, 2021–2025        68

FIGURE 30            HUMANIZED MOUSE AND RAT MODEL MARKET: PATENT ANALYSIS, 2014–2024 71

FIGURE 31            HUMANIZED MOUSE AND RAT MODEL MARKET: PORTER’S FIVE FORCES ANALYSIS       84

FIGURE 32            INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS            85

FIGURE 33            KEY BUYING CRITERIA, BY END USER    86

FIGURE 34            AI USE CASES     88

FIGURE 35           HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE,

2023–2030 (THOUSAND UNITS)  91

FIGURE 36            HUMANIZED MOUSE AND RAT MODEL MARKET: NORTH AMERICA SNAPSHOT 133

FIGURE 37            HUMANIZED MOUSE AND RAT MODEL MARKET: ASIA PACIFIC SNAPSHOT          158

FIGURE 38            REVENUE ANALYSIS OF KEY PLAYERS IN HUMANIZED MOUSE AND

RAT MODEL MARKET, 2020−2024              187

FIGURE 39            MARKET SHARE ANALYSIS OF HUMANIZED MOUSE AND RAT MODEL

MARKET, 2024    188

FIGURE 40            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF

KEY VENDORS, 2024        190

FIGURE 41            COMPANY VALUATION AND FINANCIAL METRICS, 2024   190

FIGURE 42            HUMANIZED MOUSE AND RAT MODEL MARKET: BRAND/PRODUCT COMPARISON         191

FIGURE 43            HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY EVALUATION

MATRIX (KEY PLAYERS), 2024     193

FIGURE 44            HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY FOOTPRINT             194

FIGURE 45            HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024        199

FIGURE 46            CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2024)             206

FIGURE 47            THE JACKSON LABORATORY: COMPANY SNAPSHOT (2024)             210

FIGURE 48            INOTIV: COMPANY SNAPSHOT (2024)     214

FIGURE 49            JSR CORPORATION: COMPANY SNAPSHOT (2024)    224

FIGURE 50            CHAMPIONS ONCOLOGY, INC.: COMPANY SNAPSHOT (2024)             228

FIGURE 51            HARBOUR BIOMED: COMPANY SNAPSHOT (2024)    235